Ceritinib as First-line Treatment for Advanced Lung Adenocarcinoma
with COX7A2L-ALK Fusion: A Case Report and Literature Review.
10.3779/j.issn.1009-3419.2023.102.15
- Author:
Jiao YUAN
1
;
Ruili PAN
2
;
Wei ZHONG
2
;
Mengzhao WANG
2
Author Information
1. Department of Respiratory Disease, Chengdu Seventh People's Hospital, Chengdu 610213, China.
2. Department of Pulmonary and Critic Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinses Academy of Medical Science, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
ALK inhibitors;
COX7A2L-ALK fusion mutation;
Lung neoplasms;
Rare ALK fusion mutation
- MeSH:
Humans;
Anaplastic Lymphoma Kinase/genetics*;
Lung Neoplasms/diagnosis*;
Crizotinib;
Adenocarcinoma of Lung/genetics*;
Protein Kinase Inhibitors/pharmacology*;
Oncogene Proteins, Fusion/genetics*
- From:
Chinese Journal of Lung Cancer
2023;26(4):319-324
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common in incidence and mortality worldwide. With the development of next generation sequencing (NGS) detection technology, more and more patients with rare anaplastic lymphoma kinase (ALK) fusion mutations were detected. A case of advanced lung adenocarcinoma with rare COX7A2L-ALK (C2:A20) fusion detected by NGS was reported in Peking Union Medical College Hospital, and all cases with rare ALK fusion mutations were searched from medical datebase from January 1, 2014 to March 31, 2021, to investigate the treatment of rare ALK fusion mutations with ALK inhibitors. The best response of the patient was assessed as partial response (PR) with Ceritinib treatment. By literature review, 22 cases of rare ALK fusion were reported in 19 articles. Combined with this case, 23 cases were analyzed. The objective response rate (ORR) was 82.6% (19/23) and disease control rate (DCR) was 95.7% (22/23) for rare ALK fusions patients treated with ALK inhibitors. Lung adenocarcinoma patients with rare ALK fusion could benefit from ALK inhibitors.
.
